Individualized cancer vaccines and antibody-drug conjugates will be among the dominant biotech innovations in cancer next ...

Morgan Stanley analyst Stephen Byrd suggested buying power companies he thought could benefit from the AI boom.

The Morgan Stanley executive is retiring to run a foundation she started that aims to bring more young women into wealth ...

The past two years have been absolutely incredible for investors in Nvidia (NASDAQ: NVDA) as shares of the semiconductor ...

Staggering demand for AI chips, dominance in the GPU market, and strong fundamentals make NVIDIA the top magnificent 7 stock ...

Companies take advantage of huge investor demand to pull forward bond issuance originally planned for next year ...

Morgan Stanley has recently reduced ING Groep NV (ING) stock rating, as announced on November 26, 2024, according to Finviz. Earlier, on October 22, 2024, Barclays had reduced the stock from a ...

On Friday, DexCom Inc (DXCM) stock saw a decline, ending the day at $80.24 which represents a decrease of $-0.33 or -0.41% from the prior close of $80.57. The stock opened at $80.03 and touched a low ...

Another ASX share that could be a buy in 2025 is wine giant Treasury Wine Estates. With the China market reopening to ...

In the words of MicroStrategy co-founder Michael Saylor, 2024 was “year zero of institutional adoption.” Speaking of Saylor, ...

For all the Trump Trade triumphalism and hysteria for AI, it’s been a tough year to make money across markets. Now even the ...

Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.